StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Canaccord Genuity Reviews BioNTech (BNTX) Post Earnings
March 21, 2024 7:29 AM
Canaccord Genuity analyst William Maughan reiterated a Buy rating and $171.00 price target on BioNTech (NASDAQ: BNTX).The analyst comments "Shares ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
BioNTech (BNTX) PT Lowered to $95 at TD Cowen
March 21, 2024 10:29 AM
BioNTech (BNTX) PT Lowered to $123 at BMO Capital
March 21, 2024 6:31 AM
BioNTech (BNTX) PT Lowered to $91 at Goldman Sachs
March 21, 2024 4:48 AM
JPMorgan Continues to See 2024 AS an 'execution year' for BioNTech (BNTX)
March 20, 2024 2:37 PM
Midday movers: Mobileye, Chipotle rise; Signet, BioNTech fall
March 20, 2024 8:12 AM
Form 20-F BioNTech SE For: Dec 31
March 20, 2024 7:58 AM
Form 6-K BioNTech SE For: Mar 20
March 20, 2024 7:34 AM
Form 6-K BioNTech SE For: Mar 20
March 20, 2024 7:12 AM
Moderna (MRNA) Trades Lower in Sympathy with BioNTech (BNTX)
March 20, 2024 7:09 AM
BioNTech SE (BNTX) Misses Q4 EPS by 46c, Misses on Revenue; Offers FY24 Revenue Guidance
March 20, 2024 6:19 AM
After earnings plunge, BioNTech pins hopes on cancer drug launches
March 20, 2024 6:17 AM
BioNTech SE (BNTX) Appoints Annemarie Hanekamp as Chief Commercial Officer
March 20, 2024 6:00 AM
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
March 20, 2024 6:00 AM
